Research programme: erythropoietin receptor agonists - Viking Therapeutics

Drug Profile

Research programme: erythropoietin receptor agonists - Viking Therapeutics

Alternative Names: EPO receptor agonists - Viking Therapeutics; LG 5640

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurogen Corporation
  • Developer Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 28 Nov 2017 Erythropoietin receptor agonists are still in preclinical trials for Anaemia in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anaemia in USA (PO)
  • 21 Mar 2017 Viking Therapeutics has patent protection and pending patent applications for erythropoietin receptor agonists in USA, Australia, Canada, China, Europe, India, Japan and Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top